Home - Products - Others - Other Targets - N-(2-Chloro-6-methylphenyl)-N-4-pyridinylurea

N-(2-Chloro-6-methylphenyl)-N-4-pyridinylurea

CAS No. 97627-24-2

N-(2-Chloro-6-methylphenyl)-N-4-pyridinylurea( —— )

Catalog No. M26317 CAS No. 97627-24-2

N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea is an anticonvulsant agent, treatment of generalized tonic-clonic and partial seizures.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 53 In Stock
2MG 29 In Stock
5MG 48 In Stock
10MG 82 In Stock
25MG 164 In Stock
50MG 259 In Stock
100MG 416 In Stock
200MG 576 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    N-(2-Chloro-6-methylphenyl)-N-4-pyridinylurea
  • Note
    Research use only, not for human use.
  • Brief Description
    N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea is an anticonvulsant agent, treatment of generalized tonic-clonic and partial seizures.
  • Description
    N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea is an anticonvulsant agent, treatment of generalized tonic-clonic and partial seizures.(In Vivo):N-(2-Chloro-6-methylphenyl)-N'-4-pyridinylurea shows anticonvulsant activity at 30 mg/kg in the initial tests with no signs of ataxia until 300 mg/kg. The activity seen with 30 mg/kg 37 is still present 4 h postdose. Compound is effective against seizures induced by maximal electroshock but does not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that Compound would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures.
  • In Vitro
    ——
  • In Vivo
    Compound shows anticonvulsant activity at 30 mg/kg in the initial tests with no signs of ataxia until 300 mg/kg. The activity seen with 30 mg/kg 37 is still present 4 h postdose. Compound is effective against seizures induced by maximal electroshock but does not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that Compound would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures. Compound is selected for clinical trials.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    nAChR| PAFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    97627-24-2
  • Formula Weight
    261.71
  • Molecular Formula
    C13H12ClN3O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (477.63 mM)
  • SMILES
    Cc1cccc(Cl)c1NC(=O)Nc1ccncc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Synthesis and anti-platelet activity of ferulamide derivativesJournal of Chinese Pharmaceutical Sciences, 2002, 54(1):41-52.
molnova catalog
related products
  • Obtustatin

    Highly potent integrin α1β1 inhibitor (IC50 = 0.8 nM for α1β1 binding to type IV collagen). Selective for α1β1 over α2β1, αIIbβ3, αvβ3, α4β1, α5β6, α9β1 and α4β7. Inhibits FGF2-stimulated angiogenesis in the chicken chorioallantoic model. Displays antitumor efficacy in a synergistic mouse model of Lewis lung carcinoma; blocks human melanoma growth in nude mice.

  • MM0299

    MM0299 is brain permeable, has anti-glioblastoma activity, inhibits lanosterol synthase (LSS), and induces EPC production in in situ GBM tumors.

  • Smurf1-IN-A01

    Smurf1-IN-A01 is a ubiquitin ligase Smad ubiquitination regulatory factor-1 inhibitor (kd: 3.664 nM).